Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses in Vitro and in Vivo
Biological and Pharmaceutical Bulletin · 2024
DOI: 10.1248/bpb.b24-00490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Kojo Arita und 10 weiteren Autor:innen. Beteiligte Einrichtung: Central Pharmaceutical Research Institute, Japan Tobacco Inc. Hauptthemen laut MEDLINE: Th17 Cells, Nuclear Receptor Subfamily 1, Group F, Member 3. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Retinoid-related orphan receptor-γ (RORγ) is a nuclear receptor that plays important roles in the development and activation of T helper type-17 (Th17) cells. In this study, we characterized the pharmacological profile of JTE-151 ((4S)-6-[(2-chloro-4-methylphenyl)amino]-4-{4-cyclopropyl-5-[cis-3-(2,2-dimethylpropyl)cyclobutyl]isoxazol-3yl}-6-oxohexanoic acid), which is a novel RORγ antagonist identified by our group. JTE-151 dissociated co-activator peptide from the human RORγ-ligand binding domain (LBD) and recruited co-repressor peptide into human RORγ-LBD, and potently inhibited the transcriptional activity of RORγ of human, mouse and rat. JTE-151 also demonstrated high selectivity against other receptors in nuclear receptor family. JTE-151 suppressed the differentiation of mouse naïve CD4+ T cells into Th17 cells without affecting the differentiation of those cells into other CD4+ T cell subsets in vitro. In addition, JTE-151 inhibited the production of interleukin-17 (IL-17) but not interferon-γ (IFN-γ) and IL-4 from activated human helper T cells in vitro. Furthermore, treatment with JTE-151 suppressed the production of IL-17 in antigen-sensitized mice and ameliorated the severity of arthritis in mice with collagen-induced arthritis regardless of treatment start date. Based on these results, we reasoned that JTE-151 could serve as a novel therapeutic compound for various autoimmune diseases linked to Th17 cells, such as psoriasis and rheumatoid arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Pharmaceutical Research Institute, Japan Tobacco Inc.
- Orphagen Pharmaceuticals, Inc.
Zitieren
APA
Arita, K., Tao, H., Crowe, P., Thacher, S., Otake, S., Kobayashi, K., Ebihara, S., Okamoto, Y., Katsuda, Y., Yamaguchi, T., & Matsushita, M. (2024). Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses in Vitro and in Vivo. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00490
Vancouver
Arita K, Tao H, Crowe P, Thacher S, Otake S, Kobayashi K, et al. Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses in Vitro and in Vivo. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00490
BibTeX
@article{Arita2024,
author = {Arita, Kojo and Tao, Haiyan and Crowe, Paul and Thacher, Scott and Otake, Sho and Kobayashi, Kazuma and Ebihara, Shin and Okamoto, Yoshihisa and Katsuda, Yoshiaki and Yamaguchi, Takayuki and Matsushita, Mutsuyoshi},
title = {Pharmacological Properties of JTE-151; A Novel Orally Available RORγ Antagonist That Suppresses Th17 Cell-Related Responses in Vitro and in Vivo},
journal = {Biological and Pharmaceutical Bulletin},
year = {2024},
doi = {10.1248/bpb.b24-00490}
}
EUVIMED